Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s12013-024-01385-8, but it redirected us to https://link.springer.com/article/10.1007/s12013-024-01385-8. The analysis below is for the second page.

Title[redir]:
Advances in ovarian tumor stem cells and therapy | Cell Biochemistry and Biophysics
Description:
Ovarian cancer is considered the most lethal among all gynecological malignancies due to its early metastatic dissemination, extensive spread, and malignant ascites. The current standard of care for advanced ovarian cancer involves a combination of cytoreductive surgery and chemotherapy utilizing platinum-based and taxane-based agents. Although initial treatment yields clinical remission in 70–80% of patients, the majority eventually develop treatment resistance and tumor recurrence. A growing body of evidence indicates the existence of cancer stem cells within diverse solid tumors, including ovarian cancer, which function as a subpopulation to propel tumor growth and disease advancement by means of drug resistance, recurrence, and metastasis. The presence of ovarian cancer stem cells is widely considered to be a significant contributor to the unfavorable clinical outcomes observed in patients with ovarian cancer, as they play a crucial role in mediating chemotherapy resistance, recurrence, and metastasis. Ovarian cancer stem cells possess the capacity to reassemble within the entirety of the tumor following conventional treatment, thereby instigating the recurrence of ovarian cancer and inducing resistance to treatment. Consequently, the creation of therapeutic approaches aimed at eliminating ovarian cancer stem cells holds great potential for the management of ovarian cancer. These cells are regarded as one of the most auspicious targets and mechanisms for the treatment of ovarian cancer. There is a pressing need for a comprehensive comprehension of the fundamental mechanisms of ovarian cancer’s recurrence, metastasis, and drug resistance, alongside the development of effective strategies to overcome chemoresistance, metastasis, and recurrence. The implementation of cancer stem cell therapies may potentially augment the tumor cells’ sensitivity to existing chemotherapy protocols, thereby mitigating the risks of tumor metastasis and recurrence, and ultimately improving the survival rates of ovarian cancer patients. Graphical Abstract

Matching Content Categories {📚}

  • Health & Fitness
  • Science
  • Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don’t know how the website earns money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, pubmed, article, google, scholar, ovarian, cas, cells, stem, central, cell, journal, research, resistance, kim, wang, tumor, clinical, molecular, chen, oncology, zhang, nature, stemness, lee, medicine, human, liu, therapy, targeting, stemlike, signaling, cancers, chemoresistance, international, yang, zhao, treatment, drug, metastasis, therapeutic, epithelial, pathway, chang, choi, breast, expression, receptor, properties, chemotherapy,

Topics {✒️}

regulating hsa-mir-139-5p/sdc4 axis microrna-3187-3p/erbb4/pi3k/akt axis akt-gsk3β-β-catenin signaling axis egfr/mtor-pi3k/aurora kinase inhibitors pi3k/akt-driven signaling axis month download article/chapter nf-κb-tnfα-pik3ca loop csf2/p-stat3 signalling pathway wnt/β-catenin signaling pathway cancer stem cells-perspectives mir-186-5p/zeb1 axis article  google scholar notch1/c-myc pathway β-catenin-abcg2 signaling cisplatin‐resistant ovarian cancer nf-κb signaling pathway clinical trait–related lncrna wnt/beta-catenin signaling trans retinoic acid ovarian cancer-initiating cells small-molecule kinase inhibitor inhibiting epithelial-mesenchymal transition chemotherapy utilizing platinum-based blocking tgf-β pathway aldh1 high expression notch-hes1 signalling pathway regulating drug-metabolizing enzymes natural plants compounds understanding er-beta signaling pi3k/akt signaling regulating fos/jun pathway cell stem cell induced cancer stem molecular therapy-nucleic acids dietary compound proanthocyanidins article cell biochemistry anti-tumor activity cancer stem cell cancer stem cell cancer stem cell‐ ovarian cancer stem cancer stem cells including ovarian cancer full article pdf epithelial ovarian cancer ovarian cancer cell related subjects accepted manuscript version promote stemness transformation stat3 signal regulation

Questions {❓}

  • Cancer stem cells: Problems for therapy?
  • Cancer stem cells: distinct entities or dynamically regulated phenotypes?
  • Ovarian cancer stem cells: still an elusive entity?
  • Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Advances in ovarian tumor stem cells and therapy
         description:Ovarian cancer is considered the most lethal among all gynecological malignancies due to its early metastatic dissemination, extensive spread, and malignant ascites. The current standard of care for advanced ovarian cancer involves a combination of cytoreductive surgery and chemotherapy utilizing platinum-based and taxane-based agents. Although initial treatment yields clinical remission in 70–80% of patients, the majority eventually develop treatment resistance and tumor recurrence. A growing body of evidence indicates the existence of cancer stem cells within diverse solid tumors, including ovarian cancer, which function as a subpopulation to propel tumor growth and disease advancement by means of drug resistance, recurrence, and metastasis. The presence of ovarian cancer stem cells is widely considered to be a significant contributor to the unfavorable clinical outcomes observed in patients with ovarian cancer, as they play a crucial role in mediating chemotherapy resistance, recurrence, and metastasis. Ovarian cancer stem cells possess the capacity to reassemble within the entirety of the tumor following conventional treatment, thereby instigating the recurrence of ovarian cancer and inducing resistance to treatment. Consequently, the creation of therapeutic approaches aimed at eliminating ovarian cancer stem cells holds great potential for the management of ovarian cancer. These cells are regarded as one of the most auspicious targets and mechanisms for the treatment of ovarian cancer. There is a pressing need for a comprehensive comprehension of the fundamental mechanisms of ovarian cancer’s recurrence, metastasis, and drug resistance, alongside the development of effective strategies to overcome chemoresistance, metastasis, and recurrence. The implementation of cancer stem cell therapies may potentially augment the tumor cells’ sensitivity to existing chemotherapy protocols, thereby mitigating the risks of tumor metastasis and recurrence, and ultimately improving the survival rates of ovarian cancer patients.
         datePublished:2024-07-03T00:00:00Z
         dateModified:2024-07-03T00:00:00Z
         pageStart:1871
         pageEnd:1892
         sameAs:https://doi.org/10.1007/s12013-024-01385-8
         keywords:
            Ovarian cancer
            Ovarian cancer stem cells (OCSCs)
            Cancer stem cells markers
            Signal path
            Therapy
            Biochemistry
            general
            Pharmacology/Toxicology
            Biotechnology
            Cell Biology
            Biological and Medical Physics
            Biophysics
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12013-024-01385-8/MediaObjects/12013_2024_1385_Figa_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12013-024-01385-8/MediaObjects/12013_2024_1385_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12013-024-01385-8/MediaObjects/12013_2024_1385_Fig2_HTML.png
         isPartOf:
            name:Cell Biochemistry and Biophysics
            issn:
               1559-0283
               1085-9195
            volumeNumber:82
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Biqing Chen
               affiliation:
                     name:Harbin Medical University
                     address:
                        name:Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jiaqi Liu
               affiliation:
                     name:Jilin University
                     address:
                        name:Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Advances in ovarian tumor stem cells and therapy
      description:Ovarian cancer is considered the most lethal among all gynecological malignancies due to its early metastatic dissemination, extensive spread, and malignant ascites. The current standard of care for advanced ovarian cancer involves a combination of cytoreductive surgery and chemotherapy utilizing platinum-based and taxane-based agents. Although initial treatment yields clinical remission in 70–80% of patients, the majority eventually develop treatment resistance and tumor recurrence. A growing body of evidence indicates the existence of cancer stem cells within diverse solid tumors, including ovarian cancer, which function as a subpopulation to propel tumor growth and disease advancement by means of drug resistance, recurrence, and metastasis. The presence of ovarian cancer stem cells is widely considered to be a significant contributor to the unfavorable clinical outcomes observed in patients with ovarian cancer, as they play a crucial role in mediating chemotherapy resistance, recurrence, and metastasis. Ovarian cancer stem cells possess the capacity to reassemble within the entirety of the tumor following conventional treatment, thereby instigating the recurrence of ovarian cancer and inducing resistance to treatment. Consequently, the creation of therapeutic approaches aimed at eliminating ovarian cancer stem cells holds great potential for the management of ovarian cancer. These cells are regarded as one of the most auspicious targets and mechanisms for the treatment of ovarian cancer. There is a pressing need for a comprehensive comprehension of the fundamental mechanisms of ovarian cancer’s recurrence, metastasis, and drug resistance, alongside the development of effective strategies to overcome chemoresistance, metastasis, and recurrence. The implementation of cancer stem cell therapies may potentially augment the tumor cells’ sensitivity to existing chemotherapy protocols, thereby mitigating the risks of tumor metastasis and recurrence, and ultimately improving the survival rates of ovarian cancer patients.
      datePublished:2024-07-03T00:00:00Z
      dateModified:2024-07-03T00:00:00Z
      pageStart:1871
      pageEnd:1892
      sameAs:https://doi.org/10.1007/s12013-024-01385-8
      keywords:
         Ovarian cancer
         Ovarian cancer stem cells (OCSCs)
         Cancer stem cells markers
         Signal path
         Therapy
         Biochemistry
         general
         Pharmacology/Toxicology
         Biotechnology
         Cell Biology
         Biological and Medical Physics
         Biophysics
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12013-024-01385-8/MediaObjects/12013_2024_1385_Figa_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12013-024-01385-8/MediaObjects/12013_2024_1385_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12013-024-01385-8/MediaObjects/12013_2024_1385_Fig2_HTML.png
      isPartOf:
         name:Cell Biochemistry and Biophysics
         issn:
            1559-0283
            1085-9195
         volumeNumber:82
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Biqing Chen
            affiliation:
                  name:Harbin Medical University
                  address:
                     name:Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jiaqi Liu
            affiliation:
                  name:Jilin University
                  address:
                     name:Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cell Biochemistry and Biophysics
      issn:
         1559-0283
         1085-9195
      volumeNumber:82
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Harbin Medical University
      address:
         name:Harbin Medical University, Harbin, China
         type:PostalAddress
      name:Jilin University
      address:
         name:Jilin University, Changchun, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Biqing Chen
      affiliation:
            name:Harbin Medical University
            address:
               name:Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jiaqi Liu
      affiliation:
            name:Jilin University
            address:
               name:Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Harbin Medical University, Harbin, China
      name:Jilin University, Changchun, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(1)

External Links {🔗}(658)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

5.71s.